Gold is about to SOAR – here’s what you need to do
Everything is lining up perfectly for a historic gold bull run. One gold research firm says they’ve found the best way to get in, for less than $10. MORE here…
Click here for full details.
George Eric Davis net worth and biography

George Davis Biography and Net Worth

Mr. George Eric Davis has been an Executive Vice President at BioMarin Pharmaceutical Inc. since December 30, 2015 and has been its General Counsel and Secretary since 2004. Mr. Davis served as Senior Vice President at BioMarin Pharmaceutical Inc. from December 2005 to March 2016. Mr. Davis served as an Assistant Secretary of BioMarin Pharmaceutical Inc. and served as its Vice President from 2004 to December 2005. He joined Biomarin Pharmaceutical Inc. in March 2004. From 2000 to 2004, he worked in the San Francisco office of Paul Hastings, Janofsky & Walker LLP, where he was an associate in the Corporate Department and served on its national securities practice committee. He serves as a Member of Supervisory Board at Prosensa Holding N.V. Mr. Davis received a B.A from the University of California, Berkeley and a J.D. from the University of San Francisco.

What is George Eric Davis' net worth?

The estimated net worth of George Eric Davis is at least $5.06 million as of July 8th, 2022. Mr. Davis owns 58,941 shares of BioMarin Pharmaceutical stock worth more than $5,059,495 as of September 29th. This net worth estimate does not reflect any other investments that Mr. Davis may own. Learn More about George Eric Davis' net worth.

How old is George Eric Davis?

Mr. Davis is currently 51 years old. There are 5 older executives and no younger executives at BioMarin Pharmaceutical. The oldest executive at BioMarin Pharmaceutical is Mr. Jean-Jacques Bienaime M.B.A., MBA, Chairman & CEO, who is 69 years old. Learn More on George Eric Davis' age.

How do I contact George Eric Davis?

The corporate mailing address for Mr. Davis and other BioMarin Pharmaceutical executives is 770 Lindaro Street, San Rafael CA, 94901. BioMarin Pharmaceutical can also be reached via phone at (415) 506-6700 and via email at [email protected] Learn More on George Eric Davis' contact information.

Has George Eric Davis been buying or selling shares of BioMarin Pharmaceutical?

During the last quarter, George Eric Davis has sold $665,820.00 in shares of BioMarin Pharmaceutical stock. Most recently, George Eric Davis sold 7,398 shares of the business's stock in a transaction on Friday, July 8th. The shares were sold at an average price of $90.00, for a transaction totalling $665,820.00. Following the completion of the sale, the executive vice president now directly owns 58,941 shares of the company's stock, valued at $5,304,690. Learn More on George Eric Davis' trading history.

Who are BioMarin Pharmaceutical's active insiders?

BioMarin Pharmaceutical's insider roster includes Jeffrey Ajer (EVP), Jean Bienaime (CEO), George Davis (EVP), Willard Dere (Director), Henry Fuchs (Insider), Michael Grey (Director), Charles Guyer (EVP), V. Lawlis (Director), Richard Meier (Director), Brian Mueller (CFO), David Pyott (Director), and Dennis Slamon (Director). Learn More on BioMarin Pharmaceutical's active insiders.

Are insiders buying or selling shares of BioMarin Pharmaceutical?

In the last twelve months, insiders at the biotechnology company sold shares 26 times. They sold a total of 183,464 shares worth more than $15,403,131.65. The most recent insider tranaction occured on August, 15th when CEO Jean Jacques Bienaime sold 3,000 shares worth more than $285,630.00. Insiders at BioMarin Pharmaceutical own 1.8 % of the company. Learn More about insider trades at BioMarin Pharmaceutical.

Information on this page was last updated on 8/15/2022.

George Eric Davis Insider Trading History at BioMarin Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/8/2022Sell7,398$90.00$665,820.0058,941View SEC Filing Icon  
5/2/2022Sell15,347$80.38$1,233,591.8666,339View SEC Filing Icon  
3/21/2022Sell6,129$81.29$498,226.41View SEC Filing Icon  
5/3/2021Sell4,673$78.30$365,895.9068,781View SEC Filing Icon  
4/19/2021Sell2,709$79.58$215,582.2271,149View SEC Filing Icon  
5/1/2020Sell12,504$89.38$1,117,607.5278,181View SEC Filing Icon  
11/26/2019Sell3,190$79.66$254,115.4068,709View SEC Filing Icon  
3/25/2019Sell3,363$87.86$295,473.1875,253View SEC Filing Icon  
9/13/2018Sell12,000$99.57$1,194,840.0074,950View SEC Filing Icon  
3/23/2018Sell3,350$81.35$272,522.5087,989View SEC Filing Icon  
3/16/2018Sell3,818$83.88$320,253.8494,634View SEC Filing Icon  
3/5/2018Sell2,105$79.04$166,379.2090,089View SEC Filing Icon  
2/1/2018Sell30,000$90.66$2,719,800.00112,942View SEC Filing Icon  
11/30/2017Sell1,200$85.64$102,768.00View SEC Filing Icon  
6/23/2017Sell9,844$96.60$950,930.4093,425View SEC Filing Icon  
6/5/2017Sell9,471$91.04$862,239.8474,342View SEC Filing Icon  
5/5/2017Sell2,500$100.34$250,850.0085,251View SEC Filing Icon  
3/16/2017Sell2,238$91.96$205,806.4875,967View SEC Filing Icon  
3/6/2017Sell1,498$93.32$139,793.3678,962View SEC Filing Icon  
8/1/2016Sell2,167$100.00$216,700.0071,158View SEC Filing Icon  
7/7/2016Sell2,167$90.00$195,030.0072,836View SEC Filing Icon  
5/10/2016Sell14,658$85.11$1,247,542.3891,894View SEC Filing Icon  
3/14/2016Sell1,996$86.21$172,075.1676,190View SEC Filing Icon  
12/16/2015Sell1,362$100.00$136,200.0066,156View SEC Filing Icon  
5/18/2015Sell2,558$125.26$320,415.08View SEC Filing Icon  
3/2/2015Sell23,000$108.31$2,491,130.00View SEC Filing Icon  
11/25/2014Sell20,000$89.75$1,795,000.00View SEC Filing Icon  
9/19/2014Sell17,536$69.75$1,223,136.00View SEC Filing Icon  
5/14/2013Sell20,000$70.34$1,406,800.00View SEC Filing Icon  
3/4/2013Sell4,000$60.18$240,720.00View SEC Filing Icon  
11/12/2012Sell99,075$48.45$4,800,183.75View SEC Filing Icon  
See Full Table

George Eric Davis Buying and Selling Activity at BioMarin Pharmaceutical

This chart shows George Eric Davis's buying and selling at BioMarin Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioMarin Pharmaceutical Company Overview

BioMarin Pharmaceutical logo
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $85.06
Low: $84.28
High: $85.65

50 Day Range

MA: $89.78
Low: $82.16
High: $96.94

2 Week Range

Now: $85.06
Low: $70.73
High: $97.76

Volume

781,705 shs

Average Volume

1,182,972 shs

Market Capitalization

$15.78 billion

P/E Ratio

327.17

Dividend Yield

N/A

Beta

0.32
Gold is about to SOAR – here’s what you need to do
Everything is lining up perfectly for a historic gold bull run. One gold research firm says they’ve found the best way to get in, for less than $10. MORE here…
Click here for full details.